NCT07393542

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

An Open Label, Randomized, Multicenter, Phase III Study of SHR-A2102 in Combination With Adebrelimab Versus Gemcitabine in Combination With Cisplatin/Carboplatin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (NEC-UC2)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 462 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.

Conditions

• Locally Advanced or Metastatic Urothelial Carcinoma

Interventions

Type	Name	Description
DRUG	SHR-A2102 and Adebrelimab	SHR-A2102 and Adebrelimab injection
DRUG	Gemcitabine and cisplatin / carboplatin	Gemcitabine injection and cisplatin injection / carboplatin injection

Timeline

• Start date: 2026-02-12
• Primary completion: 2027-09-01
• Completion: 2030-06-01
• First posted: 2026-02-06
• Last updated: 2026-03-03

Locations

1 site across 1 country: China